Oncology

Latest News

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com
Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

June 19th 2025

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com
Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

June 18th 2025

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Edward Arrowsmith, MD, MPH
January 10th 2024

How Tennessee Oncology Navigates Clinical Pathway Challenges and Advancements: Dr Edward Arrowsmith

Hayden E. Klein
Edward "Ted" Arrowsmith, MD, MPH, medical director for pathways at OneOncology and managing partner at Tennessee Oncology, talks about challenges and changes in clinical pathways and the importance of keeping them updated.
Cancer awareness ribbons | SewcreamStudio - stock.adobe.com
January 8th 2024

Cancer Detection Rates Dropped Due to COVID-19 Disruptions, Study Finds

Pearl Steinzor
Cancer incidence fell by 8.7% across all cancer sites during the first year of the pandemic, according to a new study.
Dr Margaret Liang on Mitigating Financial Toxicity for Patients With Cancer
January 6th 2024

Dr Margaret Liang on Mitigating Financial Toxicity for Patients With Cancer

Pearl Steinzor Rose McNulty
Margaret Liang, MD, MSHPM, gynecologic oncologist and health services researcher and director, Gynecologic Oncology Fellowship Program, Cedars-Sinai Cancer Center, discusses financial toxicity in cancer care and how institutions can help alleviate the financial burden for patients.
Dr Amy Laughlin on At-Home Cancer Care Costs, Advancements
January 3rd 2024

Dr Amy Laughlin on At-Home Cancer Care Costs, Advancements

Brooke McCormick
Amy Laughlin, MD, MSHP, of Orlando Health commented on at-home cancer care costs and shared her predictions on how at-home cancer care will evolve.
Dr Kathi Mooney
January 3rd 2024

Dr Kathi Mooney Discusses Improving Patients' Quality of Life Through Technology

Brooke McCormick
Kathi Mooney, PhD, RN, FAAN, of the University of Utah, discussed technologies she and her team developed to help improve the quality of life of patients with cancer and their families.
Highlights From ASCO 2023
January 3rd 2024

ICYMI: Highlights From ASCO 2023

Rose McNulty
The most-read content from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including the latest findings in ongoing clinical trials, a panel discussion on Medicare oncology payment models, and the importance of alignment between clinicians and payers on clinical pathways.
The top 5 Institute for Value-Based Medicine content of 2023
December 27th 2023

Top 5 Content From Institute for Value-Based Medicine® Events in 2023

Laura Joszt, MA
In 2023, there were 18 oncology and 7 population health Institute for Value-Based Medicine® events cohosted with organizations such as Optum, OneOncology, Vanderbilt Ingram Cancer Center, Duke Health, Cleveland Clinic, and Memorial Sloan Kettering Cancer Center.
The Top 5 Oncology Articles of 2023
December 22nd 2023

Top 5 Most-Read Oncology Articles of 2023

Rose McNulty
Our most-read oncology content of 2023 included meeting coverage, research on an algorithm using patient-reported outcomes to predict hospital visits, and the launch of an National Comprehensive Cancer Network pilot project aiming to measure health equity.
Global-vegefox.com-stock.adobe.com
December 21st 2023

New Study Reveals Global Disparities in Access to Multiple Myeloma Cell Therapies

Giuliana Grossi
“Unfortunately, limited access to these therapies worldwide appears to be a major challenge,” the researchers wrote.
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
December 18th 2023

Dr Tiago Biachi Discusses Precision Medicine Advancements in Solid Tumors

Pearl Steinzor
Tiago Biachi de Castria, MD, PhD, associate member in the Department of Gastrointestinal Oncology at Moffitt Cancer Center, discusses how precision medicine tools have aided oncologists in treating patients with solid tumors, while reducing overall toxicity.
Highlights ACCC 2023 Annual Meeting and Cancer Center Business Summit
December 15th 2023

ICYMI: Highlights From ACCC Spring 2023

Rose McNulty
Our most-read coverage from the Association of Community Cancer Centers (ACCC) 2023 Annual Meeting and Cancer Center Business Summit highlighted ongoing issues in oncology policy and practice.
FDA on Paper Texture | Image credit: Araki Illustrations - stock.adobe.com
December 15th 2023

FDA Approves Belzutifan for Advanced RCC After PD-1 or PD-L1 Inhibition and a VEGF-TKI

Rose McNulty
The approval of belzutifan, an oral hypoxia-inducible factor-2 alpha inhibitor, provides a new option for patients with advanced renal cell carcinoma (RCC) following treatment with a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
Highlights From the 2023 Community Oncology Conference
December 12th 2023

ICYMI: Highlights From the 2023 Community Oncology Conference

Rose McNulty
Our top coverage from this year’s Community Oncology Conference, hosted by the Community Oncology Alliance, included discussions around alternative payment models, shifts in the community oncology landscape in recent decades, and the need for reform in several areas.
stethoscope on charts - amazing studio - stock.adobe.com
December 8th 2023

California Aims for Equity by Redefining Cancer Care

Giuliana Grossi
Authors highlight key aspects of the California Cancer Care Equity Act, including its focus on Medi-Cal beneficiaries, the requirement for managed care plans to contract with specialized cancer centers, and the definition of complex cancers.
Quit Smoking - s@photo - stock.adobe.com
December 7th 2023

Research Reveals the Role of Structural Racism in Lung Cancer Risk

Giuliana Grossi
Spanning 22 studies, the analysis illuminated housing disparities, occupational hazards, unequal health care access, economic inequality, and discriminatory industry practices and how they collectively contribute to heightened lung cancer risks.
FDA logo on textured paper | Image credit: Araki Illustrations - stock.adobe.com
December 2nd 2023

FDA Grants Priority Review to Enfortumab Vedotin + Pembrolizumab in Metastatic Urothelial Cancer

Jordyn Sava
Positive data from the phase 3 EV-302 trial of enfortumab vedotin with pembrolizumab in locally advanced or metastatic urothelial cancer have shifted the landscape.
Hospital | Image credit: Andrii - stock.adobe.com
December 1st 2023

Gaps in Access to Cancer Care Resources May Contribute to Racial, Ethnic Disparities

Rose McNulty
Researchers found that core oncology services were less likely to be available at hospitals serving racial and ethnic minority groups compared with other hospitals in the United States.
empty prescription bottle | Image credit: Diomedes de jesus - stock.adobe.com
November 21st 2023

IQVIA Report Spotlights Shortages for Pain, Obesity, and Oncology Therapies

Skylar Jeremias
A new report from IQVIA provides an overview of current US drug shortages, shedding light on major areas of concern, such as medications to address pain, cardiovascular conditions, obesity and diabetes, and multiple forms of cancer.
Dr Alyson Moadel-Robblee on Effective Distress Screening and Support Systems for Patients With Cancer
November 17th 2023

Dr Alyson Moadel-Robblee on Effective Distress Screening and Support Systems for Patients With Cancer

Pearl Steinzor Rose McNulty
Alyson Moadel-Robblee, PhD, deputy director of community engagement and cancer health equity at Montefiore Einstein Comprehensive Cancer Center, discussed the center's evolving patient distress screening process and the Bronx Oncology Living Daily support program for patients with cancer.
Nashville Oncology Associates Now Part of The US Oncology Network
November 16th 2023

Nashville Oncology Associates Now Part of The US Oncology Network

The US Oncology Network now has more than 2400 providers who treat over 1.4 million patients annually at approximately 600 sites of care in 30 states.
Ian Flinn, MD, PhD | Image credit: Tennessee Oncology
November 16th 2023

Ian Flinn, MD, PhD, to Serve as Chief Scientific Officer for Greco-Hainsworth Tennessee Oncology Centers for Research

AJMC Staff
The centers for research are named for Anthony Greco, MD, and John Hainsworth, MD, who founded Sarah Cannon in 1993 as Tennessee Oncology physician researchers.
Female patient and doctor - Dragana Gordic - stock.adobe.com
November 14th 2023

Racial Discrimination in Cancer Care Has Long-Term Impact on Patients, Study Shows

Giuliana Grossi
“The silencing of Black cancer patient voices impacted patients’ health care utilization and had implications for their physical health,” the authors wrote.
Overcoming Challenges to Value-Based Care Implementation: Grant Andres
November 10th 2023

Overcoming Challenges to Value-Based Care Implementation: Grant Andres

Rose McNulty
In an interview with The American Journal of Managed Care®, Grant Andres, BSc, DC, BSN, MSN-RN, senior director of clinical operations at Arizona Oncology, discussed the nuances of successfully implementing value-based care initiatives across a large organization.
dr amy laughlin
November 2nd 2023

Dr Amy Laughlin on the Benefits of At-Home Cancer Care

Brooke McCormick
Amy Laughlin, MD, MSHP, of Orlando Health gave a preview of the topic she is presenting on at today's American Journal of Managed Care®’s Institute for Value-Based Medicine® event in New York City.
dr kathi mooney
November 1st 2023

Dr Kathi Mooney Previews Oncology Hospital at Home Presentation

Brooke McCormick
Kathi Mooney, PhD, RN, FAAN, of the University of Utah, gave a preview of "The Oncology Hospital at Home," the presentation she is giving at The American Journal of Managed Care®’s Institute for Value-Based Medicine® event on November 2 in New York City.
dr saira jan
October 30th 2023

Dr Saira Jan Details Current, Future Cost Savings From Oncology Therapeutics Home Infusion Program

Brooke McCormick
Saira Jan, PharmD, MS, of Horizon Blue Cross Blue Shield of New Jersey, discussed cost savings that occurred so far from their collaborative pilot program with Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health and also noted those they predict to occur as the program continues.
IVBM logo | Image credit: AJMC
October 27th 2023

Collaboration Is Key to Execute Value-Based Care for Patients With Cancer

Rose McNulty
Coverage of the Institute for Value-Based Medicine session with Zangmeister Cancer Center, Columbus, Ohio.
dr saira jan
October 27th 2023

Dr Saira Jan Explains Oncology Therapeutics Home Infusion Pilot Program

Brooke McCormick
Saira Jan, PharmD, MS, of Horizon Blue Cross Blue Shield of New Jersey, provides an overview of their collaborative pilot program with Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health, discussing the program's origin, objectives, and beyond.
IVBM logo | Image credit: AJMC
October 26th 2023

Multiple Perspectives of Managing Cancer From the Multidisciplinary Team at Vanderbilt

Laura Joszt, MA
Coverage from the Institute for Value-Based Medicine event with Vanderbilt University Medical Center.
IVBM logo | Image credit: AJMC
October 26th 2023

Raising the Bar for Precision Oncology and Clinical Research in a Community Practice Setting

Mary Caffrey
Coverage from the Institute for Value-Based Medicine session with Florida Cancer Specialists & Research Institute.
<1
...
789101112131415
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo